Welcome to our dedicated page for Genetron Holdings news (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings stock.
Genetron Holdings Limited (NASDAQ: GTH) is a leading precision oncology platform company based in China. With a focus on cancer molecular profiling, Genetron leverages advanced technologies in molecular biology and data science to revolutionize cancer treatment.
The company's extensive portfolio spans various stages of cancer management, including early screening, diagnosis, treatment recommendations, and continuous monitoring. Some of its flagship services and products include:
- HCCscreen: A proprietary assay for the early detection of liver cancer.
- 8-gene Lung Cancer Assay: An in-vitro diagnostic tool based on semiconductor sequencing for lung cancer detection.
- Genetron 3D Biochip Reading Instrument and Genetron S5 and S2000: Advanced sequencers for gene detection and panel sequencing.
- IDH1/TERT Gene Assays: Diagnostic assays for glioma.
In addition, Genetron has developed a ctDNA Lung Cancer Assay targeting mutations in the epidermal growth factor receptor gene. The company collaborates with global biopharmaceutical firms to offer tailored genomics research and clinical development services.
Recently, Genetron announced a definitive Agreement and Plan of Merger with New Genetron Holding Limited and Genetron New Co Limited. As part of the merger, Genetron will become a wholly-owned subsidiary of the parent company in a transaction valued at approximately US$126.0 million. This merger signifies a pivotal transformation, taking the company private and enhancing its strategic flexibility.
The merger completion, expected in the first quarter of 2024, is subject to customary closing conditions, including shareholder votes and regulatory approvals. Upon completion, Genetron's American Depositary Shares (ADSs) will be delisted from the Nasdaq Global Market, and the company will terminate its ADS program. The company aims to finalise this transition efficiently to focus on its long-term vision and goals.
For the latest updates and detailed information on Genetron Holdings Limited and its innovative contributions to precision oncology, please visit their Investor Relations page.
Genetron Holdings Limited (NASDAQ: GTH) announced the publication of a research article in Clinical and Translational Medicine highlighting its Mutation Capsule™ technology. The study focuses on detecting minimal residual disease (MRD) in hepatocellular carcinoma using circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Key findings reveal the effectiveness of the UPTS method in predicting recurrence-free survival rates. The company is collaborating with AstraZeneca R&D China to develop personalized assays, with plans for commercialization within the year.
Genetron Holdings Limited (NASDAQ: GTH) reported its unaudited preliminary financial results for Q4 and full year 2021. Q4 revenue rose 9.6% to RMB146.9 million ($23.0 million), driven by a 66.4% increase in IVD revenue. Full year revenue grew 25.3% to RMB532.0 million ($83.5 million). While gross margin expanded to 63.5%, operating loss increased to RMB183.8 million ($28.8 million) due to rising operational costs. Genetron anticipates Q1 2022 revenue of approximately RMB106 million, projecting a full year 2022 revenue growth of 10-20% compared to 2021.
Genetron Holdings Limited (Nasdaq: GTH), a leader in precision oncology in China, announced participation in the 25th Credit Suisse Asian Investment Conference. Management members, CEO Sizhen Wang and CFO Evan Yu, will hold virtual investor meetings on March 30, 2022.
Genetron specializes in molecular profiling tests, early cancer screening, and companion diagnostics, utilizing advanced technologies in molecular biology and data science for cancer treatment. For more details, interested parties can reach out to Credit Suisse for more information.
Arima Genomics, Inc. has successfully closed a $7 million Series B Preferred Stock financing round, with participation from both new and existing investors, including Genetron Health and Agilent Technologies. The funds aim to accelerate innovation and expand the company’s capabilities in 3D genomics, which provides crucial insights into the structure of genomes, enhancing research and therapeutic development. Arima's technologies are increasingly recognized in precision oncology, with over 600 global customers and more than 200 peer-reviewed studies leveraging its products.
Genetron Holdings Limited (NASDAQ: GTH) announced it will release its unaudited financial results for Q4 and the full year ending December 31, 2021, on March 29, 2022, before US market opening. The company specializes in precision oncology and offers molecular profiling tests and cancer screening products.
The management will hold a conference call at 8:30 a.m. ET on the same day, accessible via multiple international numbers. Detailed information is available on the company's investor relations website.
Genetron Holdings Limited (NASDAQ: GTH) has entered a collaboration with HUTCHMED (China) Limited to develop a companion diagnostic test for ORPATHYS® (savolitinib) targeting non-small cell lung cancer (NSCLC) in China. The initiative involves validating Genetron's approved 8-gene Lung Cancer Assay for clinical use. ORPATHYS® has shown efficacy in treating advanced solid tumors with MET exon 14 skipping alterations. This partnership aims to enhance patient access to targeted therapies, leveraging Genetron's advanced diagnostic capabilities in a key market where over a third of lung cancer patients reside.
Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, announced participation in two virtual investor conferences. Management, including CEO Sizhen Wang and CFO Evan Xu, will conduct a fireside chat on February 16, 2022, at 8:00 am EST, and have investor meetings on February 15-16 at the BTIG MedTech Conference. Additionally, they will hold meetings on February 17-18 at the 11th Annual SVB Leerink Global Healthcare Conference. Genetron specializes in molecular profiling and cancer management solutions.
Genetron Holdings Limited (Nasdaq: GTH) announced its full year 2021 revenue guidance, projecting approximately RMB 530 million, reflecting a 25% increase from 2020. CEO Sizhen Wang highlighted achievements in a challenging COVID-19 environment, showcasing robust growth driven by in-hospital IVD sales and partnerships with AstraZeneca and Fosun Pharma. The company is advancing its early screening strategies for liver cancer and developing a multi-omics blood-based colorectal cancer early screening assay. An earnings call is scheduled for March to discuss Q4 and full year results.
Genetron Health (NASDAQ: GTH) has launched the "Lung Loves New Life" genetic testing campaign in partnership with the China Primary Health Care Foundation. As the sole corporate donor, Genetron will provide free testing services to 10,000 lung cancer patients using its 8-gene lung cancer assay. This initiative aims to enhance treatment personalization for non-small-cell lung carcinoma (NSCLC) patients, particularly those with rare gene mutations. The 8-gene assay utilizes Genetron’s One-Step Seq Method, enabling faster testing and reporting, contributing to precision medicine in cancer care.
Genetron Holdings Limited (NASDAQ: GTH) reported its third quarter 2021 financial results, showing a total revenue of RMB 152.5 million (US $23.7 million), a 36.2% YoY increase. LDT revenue grew by 30.2% to RMB 93.0 million (US $14.4 million), while IVD revenue soared by 70.5% to RMB 51.3 million (US $8.0 million). Gross margin improved to 69.0% from 62.2% in 2020. However, the company recorded a loss of RMB 130.1 million (US $20.2 million). Genetron anticipates a challenging Q4 due to China's COVID-19 restrictions and revised its 2021 revenue guidance to around RMB 530 million, reflecting 24.9% growth.
FAQ
What is the market cap of Genetron Holdings (GTH)?
What does Genetron Holdings Limited specialize in?
What are some of Genetron's key products?
What recent corporate action has Genetron announced?
What is HCCscreen?
What is the significance of Genetron's merger?
What happens to Genetron's ADSs after the merger?
Who are the major stakeholders involved in the merger?
When is the merger expected to complete?
What services does Genetron offer in genomics research?
Where can I find more information about Genetron's financial filings?
